Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Minority Interest (2021 - 2025)

Nutex Health's Minority Interest history spans 5 years, with the latest figure at $94.0 million for Q4 2025.

  • For Q4 2025, Minority Interest rose 67.56% year-over-year to $94.0 million; the TTM value through Dec 2025 reached $94.0 million, up 67.56%, while the annual FY2025 figure was $94.0 million, 67.56% up from the prior year.
  • Minority Interest for Q4 2025 was $94.0 million at Nutex Health, down from $120.9 million in the prior quarter.
  • Across five years, Minority Interest topped out at $120.9 million in Q3 2025 and bottomed at -$8.3 million in Q3 2021.
  • The 5-year median for Minority Interest is $19.3 million (2024), against an average of $36.3 million.
  • The largest YoY upside for Minority Interest was 35179.88% in 2022 against a maximum downside of 68.2% in 2022.
  • A 5-year view of Minority Interest shows it stood at $76.9 million in 2021, then crashed by 68.2% to $24.5 million in 2022, then decreased by 27.84% to $17.7 million in 2023, then skyrocketed by 217.76% to $56.1 million in 2024, then surged by 67.56% to $94.0 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Minority Interest are $94.0 million (Q4 2025), $120.9 million (Q3 2025), and $101.6 million (Q2 2025).